SunTrust analyst Bruce Nudell lowered his price target on Abiomed to $340 after its Q4 revenue miss and below-consensus initial top-line forecasts for FY20. The analyst maintains his Buy rating however and calls the stock a “unique investment opportunity” with a bullish view about the prospects for its “temporary mechanical circulatory support” system.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.